ANIK Anika Therapeutics Inc

Price (delayed)

$25.03

Market cap

$371.69M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.64

Enterprise value

$325.73M

Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Anika Therapeutics partners with clinicians to understand what they need ...

Highlights
The company's gross profit rose by 10% YoY and by 2.2% QoQ
Anika Therapeutics's debt has decreased by 7% YoY
ANIK's equity is down by 26% year-on-year and by 22% since the previous quarter
Anika Therapeutics's quick ratio has decreased by 19% YoY and by 7% from the previous quarter

Key stats

What are the main financial stats of ANIK
Market
Shares outstanding
14.85M
Market cap
$371.69M
Enterprise value
$325.73M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.73
Price to sales (P/S)
2.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.95
Earnings
Revenue
$166.66M
EBIT
-$87.64M
EBITDA
-$71.19M
Free cash flow
-$7.22M
Per share
EPS
-$5.64
Free cash flow per share
-$0.49
Book value per share
$14.5
Revenue per share
$11.37
TBVPS
$17.63
Balance sheet
Total assets
$270.63M
Total liabilities
$58.37M
Debt
$26.9M
Equity
$212.27M
Working capital
$132.25M
Liquidity
Debt to equity
0.13
Current ratio
5.26
Quick ratio
3.5
Net debt/EBITDA
0.65
Margins
EBITDA margin
-42.7%
Gross margin
61.9%
Net margin
-49.6%
Operating margin
-52.6%
Efficiency
Return on assets
-26.1%
Return on equity
-32%
Return on invested capital
-48%
Return on capital employed
-36.6%
Return on sales
-52.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ANIK stock price

How has the Anika Therapeutics stock price performed over time
Intraday
-2.26%
1 week
-2.3%
1 month
-2.95%
1 year
-8.08%
YTD
10.46%
QTD
-1.46%

Financial performance

How have Anika Therapeutics's revenue and profit performed over time
Revenue
$166.66M
Gross profit
$103.09M
Operating income
-$87.64M
Net income
-$82.67M
Gross margin
61.9%
Net margin
-49.6%
Anika Therapeutics's operating income has plunged by 187% from the previous quarter
Anika Therapeutics's operating margin has plunged by 181% from the previous quarter
The company's gross profit rose by 10% YoY and by 2.2% QoQ
The revenue has grown by 7% YoY and by 2.1% from the previous quarter

Growth

What is Anika Therapeutics's growth rate over time

Valuation

What is Anika Therapeutics stock price valuation
P/E
N/A
P/B
1.73
P/S
2.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.95
ANIK's price to book (P/B) is 26% more than its last 4 quarters average of 1.4
ANIK's equity is down by 26% year-on-year and by 22% since the previous quarter
ANIK's P/S is 39% below its 5-year quarterly average of 3.7 but 2.3% above its last 4 quarters average of 2.2
The revenue has grown by 7% YoY and by 2.1% from the previous quarter

Efficiency

How efficient is Anika Therapeutics business performance
The ROIC has dropped by 189% since the previous quarter
The company's return on sales has shrunk by 184% QoQ

Dividends

What is ANIK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANIK.

Financial health

How did Anika Therapeutics financials performed over time
The total assets has decreased by 22% YoY and by 18% QoQ
Anika Therapeutics's quick ratio has decreased by 19% YoY and by 7% from the previous quarter
Anika Therapeutics's debt is 87% lower than its equity
The debt to equity is up by 30% since the previous quarter and by 30% year-on-year
ANIK's equity is down by 26% year-on-year and by 22% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.